fashion -WSS

fashion

author：explore 2025-10-01 10:34:29 - browse：941

Five elderly people have been blinded in one eye by a severe side effect after receiving injections of a newly approved treatment for eye disease from Apellis Pharmaceuticals. The frequency of this side effect — a severe type of eye inflammation — is low but its cause remains unknown.

The new safety information related to the Apellis drug, called Syfovre, was presented Saturday by a committee of eye disease experts at the annual meeting of the American Society of Retinal Specialists (ASRS).

Apellis cooperated with the ASRS analysis but the company also announced its own internal review Saturday that found fewer cases of retinal occlusive vasculitis, a type of severe eye inflammation that blocks blood flow to the retina and can result in blindness. The rate of retinal occlusive vasculitis reported remains “very rare,” the company said, adding that there is no evidence linking the drug product or its manufacturing to the severe side effect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Sanders adds drug shortage policies to pandemic preparedness bill

focus

WSS

STAT Readout Newsletter: Biotech news today

Listen: Wegovy in the brain & pivotal Alzheimer's data

How AI can help patients find reliable information about doctors

Custom gene therapy hints at new path for rare disease treatments

Sanders adds drug shortage policies to pandemic preparedness bill

Health tech investors get more selective as pandemic boom fades

Wikipedia

fashion

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Medicare details structure of new drug price negotiation program

Study on Amgen’s bispecific immunotherapy produces positive data

Apple is now the first public company to be valued at $3 trillion

Group opposing PBM reform sets lobbying record

Medicare details structure of new drug price negotiation program

Is there really a nursing shortage in the U.S.?

Walensky prepares to leave CDC — and Congress — behind

Roche acquires Telavant from Roivant, adding experimental IBD treatment

explore

STAT Summit: How researchers deal with rejection

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Medicare to cover more brain scans for Alzheimer’s patients

Roche drug slashes death risk in early

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

entertainment

entertainment

explore